Canterbury DHB
SCT is now rarely done following the introduction of imatinib and related drugs. For the patient who fails to respond to imatinib, relapses through imatinib treatment, or is not suitable for this drug, allografting will need to be considered, as well as the use of an alternative more active tyrosine kinase inhibitor.
This is performed following either:
If a RIC SCT is done for CML then Fludarabine/Melphalan/Alemtuzumab conditioning could be used.
Topic Code: 9179